Patients with TP53 and ATM comutation compose a subgroup of patients with NSCLC associated with an increased tumor mutation burden and better response to immune checkpoint inhibitors; TP53 and ATM may be a clinically relevant biomarker in guiding immunotherapy treatment of NSCLC. Here, ATM is linked to non-small cell lung carcinoma.